Fesoterodine
![]() | |
![]() | |
Clinical data | |
---|---|
Trade names | Toviaz |
AHFS/Drugs.com | Monograph |
MedlinePlus | a609021 |
License data |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 52% (active metabolite) |
Protein binding | 50% (active metabolite) |
Metabolism | Liver (CYP2D6- and 3A4-mediated) |
Elimination half-life | 7–8 hours (active metabolite) |
Excretion | Kidney (70%) and fecal (7%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.184.854 ![]() |
Chemical and physical data | |
Formula | C26H37NO3 |
Molar mass | 411.586 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Fesoterodine (INN, used as the fumarate under the brand name Toviaz) is an antimuscarinic drug developed by Schwarz Pharma AG to treat overactive bladder syndrome (OAB).[2] It was approved by the European Medicines Agency in April 2007,[3] the US Food and Drug Administration on October 31, 2008 [4] and Health Canada on February 9, 2012.[5]
Fesoterodine is a prodrug. It is broken down into its active metabolite, desfesoterodine, by plasma esterases.
Efficacy[]
Fesoterodine has the advantage of allowing more flexible dosage than other muscarinic antagonists.[6] Its tolerability and side effects are similar to other muscarinic antagonists and as a new drug seems unlikely to make great changes in practices of treatment for overactive bladder.[6]
A Japanese study from 2017, showed that urgency and urge incontinence are improved after 3 days administration of the drug, with full efficacy able to be judged after 7 days administration. Overactive bladder was found to be resolved in 88% of patients after seven days usage. [7]
References[]
- ^ "Fesoterodine (Toviaz) Use During Pregnancy". Drugs.com. 7 November 2019. Retrieved 12 August 2020.
- ^ "Fesoterodine, New Drug Candidate For Treatment For Overactive Bladder – Pfizer To Acquire Exclusive Worldwide Rights". Medical News Today. 17 April 2006.
- ^ "Toviaz: European Public Assessment Report, Revision 3 - Published 02/06/08". European Medicines Agency. 2 June 2008. Archived from the original on 2008-04-01.
- ^ "Pfizer's Toviaz (fesoterodine fumarate) Receives FDA Approval for the Treatment of Overactive Bladder" (Press release). Pfizer Inc. 2008-10-31. Retrieved 2008-11-06.
- ^ "Notice of Decision for TOVIAZ". Archived from the original on 2012-04-23. Retrieved 2012-04-20.
- ^ a b Vella M, Cardozo L (September 2011). "Review of fesoterodine". Expert Opinion on Drug Safety. 10 (5): 805–8. doi:10.1517/14740338.2011.591377. PMID 21639817. S2CID 9653506.
- ^ "Sato N, Fuji K, Ogawa Y (2017). "Transactions of The Showa University Society: The 335th Meeting". The Showa University Journal of Medical Sciences. 29 (2): 201–217. doi:10.15369/sujms.29.201. ISSN 2185-0968.
External links[]
- "Fesoterodine". Drug Information Portal. U.S. National Library of Medicine.
- Muscarinic antagonists
- Prodrugs
- Primary alcohols
- Isobutyrate esters
- Pfizer brands
- Diisopropylamino compounds
- Phenol esters
- Genito-urinary system drug stubs